论文部分内容阅读
目的分析与观察辛伐他汀联合参麦治疗高血脂症的临床方法和疗效。方法选取我院2011年9月～2012年10月收治高血脂症患者86例,随机分为对照组和观察组各43例,两组均采用常规辛伐他汀治疗,观察组每24h辅用40ml参麦注射液加5%葡萄糖250ml静脉输注1次,30天后测定血浆总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)、高敏C反应蛋白(hs～CRP)、甘油三酯(TG)和低密度脂蛋白胆固醇(LDL-C),对比两组数据。结果经1个疗程30天后,通过两组比较,辅用参麦的观察组较对照组HDL-C明显升高,CRP、TC及LDL-C下降,对比明显,P<0.05有统计学意义。结论采用辛伐他汀联合参麦治疗高血脂疗可有效降低高敏C反应蛋白水平,效果较好,缩短病程,值得临床广泛应用。
Objective To analyze and observe the clinical efficacy and clinical efficacy of simvastatin combined with Shenmai in the treatment of hyperlipidemia. Methods Eighty-six patients with hyperlipidemia were selected from September 2011 to October 2012 in our hospital. They were randomly divided into control group and observation group of 43 cases. Both groups were treated with routine simvastatin. The observation group was treated with 40 ml Shenmai injection plus 5% glucose 250ml intravenously once a day, 30 days after the determination of plasma total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), high-sensitivity C-reactive protein (hs ~ CRP), triglyceride TG) and low-density lipoprotein cholesterol (LDL-C), compared two sets of data. Results After one course of treatment for 30 days, HDL-C, CRP, TC and LDL-C in the Shenmai observation group were significantly higher than those in the control group after two courses of treatment. P <0.05 was considered statistically significant. Conclusion Simvastatin combined with Shenmai treatment of hyperlipidemia can effectively reduce high-sensitivity C-reactive protein level, the effect is better, shorten the course of the disease, it is widely used in clinical.